Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy
- 208 Downloads
Dasatinib is a second-generation (2G) tyrosine-kinase inhibitor (TKI) approved for the first- and second-line treatment of chronic myeloid leukemia (CML) patients. Though highly effective, dasatinib displays a distinct safety profile, with pleural effusion (PE) occurring in a significant proportion of patients [1, 2]. Among factors associated with dasatinib-related PE, concomitant pulmonary and cardiovascular diseases have emerged as the most common . Bosutinib is another 2G-TKI that has proved to be effective in CML patients failing previous TKIs, with relatively limited toxicity, represented mainly by gastrointestinal and cutaneous side effects . Generally considered safe from the cardiovascular point of view, bosutinib has been seldom associated with PE . To date, little is known about cross-intolerance between dasatinib and bosutinib, and scarce data have been reported on the incidence of PE with bosutinib in patients with pleuropulmonary toxicity under...
M. Tiribelli designed the study, analyzed the data, and wrote the draft of the manuscript. All authors provided clinical data, helped in the analysis and interpretation of the results, critically revised the manuscript, and approved the final draft for submission.
Compliance with ethical standards
Conflict of interest
M. Tiribelli and G. Binotto received honoraria from Novartis, BMS, Pfizer, and Incyte. A. Iurlo received honoraria from Novartis, Pfizer, and Incyte. M. Bonifacio received honoraria from Amgen, Incyte, Pfizer, and Novartis. M. Crugnola received honoraria from Novartis, Incyte, and Jassen.
All other authors have no conflict of interest to report.
This was a non-interventional retrospective evaluation of patient’s chart data, so no ethical approval for its conduct was necessary; for the same reason, no informed consent had to be obtained from the included patients.
- 2.Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M (2018) Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Ann Hematol 97:95–100CrossRefGoogle Scholar
- 3.Latagliata R, Breccia M, Fava C, Stagno F, Tiribelli M, Luciano L, Gozzini A, Gugliotta G, Annunziata M, Cavazzini F, Ferrero D, Musto P, Capodanno I, Iurlo A, Visani G, Crugnola M, Calistri E, Castagnetti F, Vigneri P, Alimena G (2013) Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematol Oncol 31:103–109CrossRefGoogle Scholar
- 4.Gambacorti-Passerini C, Cortes JE, Lipton JH, Kantarjian HM, Kim DW, Schafhausen P, Crescenzo R, Bardy-Bouxin N, Shapiro M, Noonan K, Leip E, DeAnnuntis L, Brümmendorf TH, Khoury HJ (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298–1307CrossRefGoogle Scholar
- 5.Kantarjian HM, Cortes JE, Kim DW, Khoury HJ, Brümmendorf TH, Porkka K, Martinelli G, Durrant S, Leip E, Kelly V, Turnbull K, Besson N, Gambacorti-Passerini C (2014) Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Blood 123:1309–1318CrossRefGoogle Scholar
- 6.Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saußele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884CrossRefGoogle Scholar
- 7.García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL, Grupo Español de Leucemia Mieloide Crónica (GELMC) (2019) Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. Ann Hematol 98:321–330CrossRefGoogle Scholar
- 8.Cortes JE, Khoury HJ, Kantarjian HM, Lipton JH, Kim DW, Schafhausen P, Matczak E, Leip E, Noonan K, Brümmendorf TH, Gambacorti-Passerini C (2016) Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol 91:1206–1214CrossRefGoogle Scholar